ObjectiveTo compare the short-term outcomes of Da Vinci robot-assisted minimally invasive esophagectomy (RAMIE) and video-assisted thoracoscopic-laparoscopic minimally invasive esophagectomy (VAMIE) for esophageal cancer. MethodsA retrospective analysis was conducted on the data of patients with esophageal cancer admitted to Gansu Provincial People's Hospital from January 2021 to February 2025. Based on the surgical method, patients were divided into a RAMIE group and a VAMIE group. Both groups underwent standard McKeown three-incision surgery and systematic three-field lymph node dissection. Intraoperative blood loss, number of lymph nodes dissected, postoperative recovery indicators, and complication rates were compared. ResultsA total of 126 patients with esophageal cancer were included, of which 109 were male and 17 were female, with an average age of (64.6±8.8) years. The RAMIE group consisted of 36 patients and the VAMIE group 90 patients. There was no statistical difference in baseline indicators such as age, sex, and body mass index between the two groups (P>0.05). The difference in operation time between the two groups was not statistically significant [305.0 (280.0, 348.0) min vs. 300.0 (268.8, 340.0) min, P=0.457]. Compared with the VAMIE group, the RAMIE group had less intraoperative blood loss [100.0 (100.0, 120.0) mL vs. 100.0 (100.0, 200.0) mL, P=0.035], more intraoperative fluid infusion [(2244.7±610.3) mL vs. (1954.4±457.9) mL, P=0.013], a higher number of lymph nodes dissected [(27.9±10.6) nodes vs. (21.3±5.1) nodes, P<0.001], and the difference in the number of lymph node dissection groups was not statistically significant [8.0 (6.0, 8.0) groups vs. 7.0 (5.0, 8.0) groups, P=0.268]. In terms of postoperative recovery indicators, compared with the VAMIE group, the RAMIE group had shorter postoperative hospital stay [12.5 (9.0, 18.0) d vs. 17.0 (14.0, 22.0) d, P＜0.001] and shorter time with tubes [9.0 (8.0, 10.0) d vs. 10.0 (9.0, 12.0) d, P=0.007]. In terms of postoperative complications, the incidence of recurrent laryngeal nerve injury in the RAMIE group was significantly lower than that in the VAMIE group (2.8% vs. 16.7%, P=0.039), there was no statistical difference in pulmonary infection, anastomosis leakage, and incision infection between the two groups (P>0.05). The total hospitalization cost of the RAMIE group was significantly higher than that of the VAMIE group (P<0.001). ConclusionRAMIE has significant advantages over VAMIE in terms of intraoperative bleeding control, the number of lymph node dissections, postoperative recovery speed, and reducing the risk of incision infection and recurrent laryngeal nerve injury, with good safety and feasibility.
As a core biomarker of non-invasive liquid biopsy, circulating tumor DNA (ctDNA) provides a breakthrough approach for minimal residual disease (MRD) monitoring in esophageal cancer. Esophageal cancer is clinically characterized by strong invasiveness, high postoperative recurrence rate, and poor prognosis. Traditional imaging and histopathological examinations are difficult to meet the clinical demand for accurate MRD identification due to limitations such as insufficient sensitivity and high invasiveness. This paper systematically reviews the biological basis and technical advances of ctDNA detection, focusing on the advantages and clinical application scenarios of core technologies including digital polymerase chain reaction, next-generation sequencing, and methylation detection. It further analyzes the core clinical value of ctDNA in esophageal cancer MRD monitoring, covering key directions such as early recurrence warning, dynamic evaluation of treatment efficacy, and optimization of individualized treatment strategies. Meanwhile, the main challenges currently faced, including insufficient technical standardization, interference from tumor heterogeneity, and lag in clinical translation, are discussed, and future development trends such as multi-omics integration and artificial intelligence-assisted diagnosis are prospected. This review aims to provide an academic reference for the precise clinical management of esophageal cancer MRD, promote the standardized application and translation of ctDNA technology in clinical practice of cardiothoracic surgery, and ultimately improve the survival prognosis of patients.